EIPICO stock (EGS38081C013): Egyptian pharma player in focus

EIPICO, a leading Egyptian pharmaceutical manufacturer, continues to serve key markets in Africa and the Middle East amid ongoing industry developments.

EIPICO, ticker symbol on the Egyptian Exchange, remains a prominent name in the North African pharmaceutical sector. The company specializes in manufacturing generic drugs and active pharmaceutical ingredients. Recent market activity shows the stock trading steadily, with shares at approximately 41.50 EGP as of early May 2026 on the EGX, according to EGX data as of 05/10/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Egyptian International Pharmaceutical Industries Company (EIPICO)
• Sector/industry: Pharmaceuticals
• Headquarters/country: Egypt
• Core markets: Egypt, Africa, Middle East
• Key revenue drivers: Generic drugs, APIs
• Home exchange/listing venue: Egyptian Exchange (EGX)
• Trading currency: EGP

EIPICO: core business model

EIPICO operates as one of Egypt's largest pharmaceutical producers, focusing on the development, manufacturing, and distribution of generic medications and active pharmaceutical ingredients (APIs). Established in 1977, the company has grown into a key player with multiple production facilities in Egypt. Its product portfolio spans antibiotics, analgesics, cardiovascular drugs, and diabetes treatments, catering primarily to local and regional demand.

The business model emphasizes cost-effective production of high-quality generics, leveraging Egypt's strategic position for exports to over 40 countries in Africa and the Arab world. EIPICO invests in R&D to expand its pipeline, including biosimilars and innovative formulations. For US investors, EIPICO offers exposure to the fast-growing emerging markets pharma sector, where demand for affordable drugs is surging.

Main revenue and product drivers for EIPICO

Revenue is predominantly driven by sales of finished dosage forms, which accounted for the majority of income in recent annual reports. Key products include antibiotics like amoxicillin and anti-diabetics such as metformin, produced in large volumes for domestic hospitals and pharmacies. Exports contribute significantly, with Sub-Saharan Africa representing a growing segment as per company disclosures.

APIs production adds another layer, supplying raw materials to regional manufacturers. In fiscal year 2024/2025 (ended June 2025), consolidated revenues reached around EGP 6.5 billion, up from prior periods, according to EIPICO reports as of 2025. This growth reflects higher volumes and favorable currency dynamics in export markets.

Industry trends and competitive position

The Egyptian pharma market is expanding at over 10% annually, driven by population growth and rising chronic disease prevalence. EIPICO holds a top-tier position locally, competing with global giants like Novartis and local peers. Its vertical integration from APIs to finished products provides cost advantages.

Regionally, EIPICO benefits from trade agreements facilitating exports. For US investors tracking ADRs or emerging market ETFs, EIPICO exemplifies resilience in non-US listed pharma with ties to US-sourced tech transfers.

Why EIPICO matters for US investors

While not directly listed in the US, EIPICO's operations intersect with American interests through partnerships and supply chains. US pharma majors often collaborate on tech for generics production. The company's exposure to USD-pegged African markets offers a hedge against EM volatility, relevant for diversified portfolios.

Conclusion

EIPICO stands as a cornerstone of Egypt's pharmaceutical industry, with a robust model centered on generics and exports. Steady trading and regional expansion underscore its stability. US investors may find value in its emerging market positioning amid global pharma shifts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.